ClinicalTrials.gg
RecruitingNCT06991946HOPE-FocusUpdated May 28, 2025

Patient-Centric Study to Assess the Impact of Genomic Profiling on the Treatment of Patients With Metastatic Breast Cancer in Spain

An observational study in Metastatic Breast Cancer, sponsored by SOLTI Breast Cancer Research Group. Recruiting at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by SOLTI Breast Cancer Research Group · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group — 4 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · SOLTI Breast Cancer Research Group.

Started
2025
the only one that year
Observational
4 of 29
1 open now
Registered
28th of 29
by date

Among the 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group, this one is the only one that started in 2025, is one of 4 observational ones, and was the 28th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

4 of the 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies in Breast Neoplasms by SOLTI Breast Cancer Research Group, or all of them as a file.
02

Study summary

HOPE Focus is an observational study that aims at promoting research against metastatic breast cancer by means of collective research led by patients (patient-centric trial). Patients with metastatic breast cancer living in Spain will voluntarily register and fulfil their journey in the study through the study's digital tool. Mainly they are prompted to answer questionnaires about their disease and expectations, and to provide a blood sample and an archival tumor biopsy. In HOPE Focus these samples will be genomically analyzed and every patient case will be presented in a multidisciplinary molecular advisory board (MAB). The MAB will issue a plain report explaining the significance of the results and will enumerate future therapeutic options that match patient history and his genomic profile, when feasible. Finally, patients will have to answer short follow-up questionnaires twice a year for 3 years.

The study data will allow us to advance implementing precision medicine to improve the management of current and specially future metastatic breast cancer patients.

Read the detailed description

HOPE Focus - SOLTI-2401 is a prospective, patient-centered research initiative designed to enhance the treatment of patients with MBC through advanced molecular diagnosis in a real-world clinical setting. It uniquely empowers patients to actively participate in their care, from inclusion and data provision to follow-up, utilizing a web-based digital tool (DT) that streamlines their entire journey within the study. The DT not only facilitates seamless communication between patients and the research team, but also serves as a comprehensive repository for relevant study information.

Patients will lead their own inclusion and participation, providing follow-up data through the DT that will guide them during all their journey in the study. After registration and after undergoing an informative interview, eligible patients will provide electronic signature of the informed consent form, and information about their demographic characteristics and relevant oncological information, all through the DT. In addition, the tool will guide them to attend the closest local partner laboratory to:

  • Sign a paper version of the informed consent form if it cannot be signed electronically.
  • Hand over a tissue block retrieved from their hospital for molecular diagnosis.
  • Provide blood for plasma extraction and ctDNA analysis if their disease is progressing to the last line of therapy (liquid biopsy).

The DT will be a reference for patients of the status of their case within the study and will be the main repository of the ICF, clinical information provided by patients, sequencing results and reports generated after Molecular Advisory Board (MAB )discussion. Finally, there will be a three-year active follow-up to capture the impact of molecular diagnosis using the DT.

At the time of disease progression and preferably before the initiation of a new line of therapy, blood will be collected at the closest venue of the partner laboratory. Plasma samples will be tested using a NGS comprehensive panel and a standard genomics report will be generated afterwards.

Participants will be required to provide an archival tumor sample (preferably from a metastatic site) that will undergo genomic characterization. FFPE blocks will be assessed at the study's central laboratory by a pathologist and H\&E slides will be digitalized. Samples with sufficient tumor content will undergo DNA extraction, quantification, and quality control. Valid samples will undergo targeted sequencing using a previously validated capture-based panel including more than 400 genes (mutations, CNA) and biomarkers such as tumor mutational burden (TMB) A standard genomic report will be generated after analysis.

Upon genomic report generation (from blood and/or tissue), a SOLTI dedicated team will present the case at the following Molecular Advisory Board (MAB) meeting. During MAB meetings patient cases will be discussed using the new genomic information and the board will issue a report enumerating the potential future therapeutic strategies to be considered.

MAB reports will be in Spanish and will include a text summarizing the interpretation of results. Reports will be addressed to the participants, but they will also be sent to their oncologists (if participating). In addition to the discussion of the molecular results and the treatment recommendations, the MABs are also intended to generate a platform where the HCPs can learn about emerging strategies in MBC management, how to interpret genomics data and embrace fruitful debates to promote continuous learning. The MAB will be gathering a multidisciplinary group of experts in BC clinical management (including medical oncologists and radiation oncologists), cancer geneticists, experts in bioethics, and pathologists. Besides permanent MAB members, physicians treating study participants will be invited to join their patient's discussion.

One month after MAB report delivery, patients will be required to answer a second questionnaire to capture if the information received was relevant for subsequent treatment decisions.

Importantly, the SOLTI-2401 HOPE-Focus Study will not provide any pharmacological intervention to participants. After MAB report delivery, patients will be treated according to local practice or will be directed to ongoing clinical trials. From this moment, patients will be under active follow-up. Periodically, the DT will require them to fill out brief clinical questionnaires to capture the subsequent treatments received. If patients fail to answer a periodic questionnaire, the study team will contact them to reasonably request for response. This follow-up period will last at least 3 years, as SOLTI has the willingness of maintaining the program if the necessary economic supports are achieved, by extending the follow-up period.

Participation of treating physicians will be highly recommended but not mandatory. Patients will be able to request the involvement of their physicians by providing the physician's name and contact details through the web-based digital tool, in accordance with the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016 (GDPR) and the Organic Law 3/2018 on Protection of Personal Data and Guarantee of Digital Rights (LOPDGDD). Only upon electronic written consent collection they will be involved. Then, they will be able to support patient participation and attend the MAB case discussion.

Obtaining patient-reported experience measures (PREMs) of certain aspects involved in cancer care and in molecular diagnosis (knowledge, expectations, concerns, etc.), will allow the design of future strategies to deliver healthcare respecting individual preferences, needs and values. At inclusion and after receiving the report with the MAB assessment, patients will fill out PREM questionnaires. Moreover, during the follow-up process patients will be inquired about their perception of the study's impact on the treatment decisions taken.

The study will be in accordance with the Declaration of Helsinki and Good Clinical Practice Guidelines and applicable regulatory requirements and in accordance with data protection regulations: GDPR and LOPDGDD. Approval of the study protocol will be from an Independent Ethics Committee.

The present initiative intends to build a collaborative patient-centric program for molecular diagnosis in patients with MBC that will facilitate the testing and implementation of novel diagnostic strategies to identify patients who may benefit from precision medicine drugs, either approved or in clinical trials. Moreover, it envisions to promote patient empowerment to live with their disease and to increasing education among HCP and other stakeholders about the potential of molecular diagnosis into MBC care.

03

Conditions studied

  • Metastatic Breast Cancer

Browse trials for

Keywords

  • molecular advisory board
  • molecular tumor board
  • genomic data
  • targeted therapy
  • patient-centric trial
  • observational trial
  • Molecular data
  • genomic analysis
  • liquid biopsy
  • tumor block
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients diagnosed with metastatic breast cancer living and being treated in Spain.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female or male patients residing in Spain.
  2. Age ≥ 18 years.
  3. Signed prior to any study-related procedures, except for registration.
  4. Self-reported (ECOG) performance status of 0-1.
  5. Patients with breast cancer in at least one of these situations:

    1. Patients recently diagnosed with ER+/- metastatic breast cancer as a recurrence during treatment and prior to initiating any treatment in the metastatic setting.
    2. Patients with metastatic breast cancer of any subtype that have progressed after at least one in the metastatic setting.

Exclusion criteria

Exclusion Criteria:

  1. Presence of a condition or abnormality that, in the opinion of the investigators, would compromise the safety of the patient or the quality of the data.
  2. Inability or refusal to commit with the procedures of the study at the moment of inclusion.
  3. More than 3 prior systemic chemotherapy or antibody-drug conjugate (ADC) regimens for disease. Note: treatments for bone metastases (eg, bisphosphonates, denosumab, etc.), targeted therapies (eg, PARP inhibitors, CDK 4/6 inhibitors, immunotherapy etc.) and hormonal therapy are not considered as prior systemic chemotherapy treatments for advanced disease.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Metastatic breast cancer of any subtype

    Patients with metastatic breast cancer of any subtype that have progressed after at least one line of treatment in the metastatic setting

    Genetic: Liquid Biopsy · Genetic: Archival Tumor DNA

  • ER+/HER2- metastatic breast cancer

    Patients recently diagnosed with ER+/HER2- metastatic breast cancer as a recurrence during adjuvant treatment and prior to initiating any treatment in the metastatic setting

    Genetic: Liquid Biopsy · Genetic: Archival Tumor DNA

Interventions

  • GeneticLiquid Biopsy

    Patients with metastatic breast cancer in disease progression will undergo a liquid biopsy

  • GeneticArchival Tumor DNA

    Patients will be prompted to request an archival tumor sample from metastatic origin (preferably) and to send it to the central laboratory for analysis

06

What researchers measure

Primary outcomes

  1. To evaluate the feasibility of incorporating a molecular diagnosis in the management of patients with metastatic breast cancer following a patient-centric strategy.

    Percentage of patients with a valid NGS test and a treatment recommendation by the Molecular Advisory Board.

    Time frame: Ongoing basis during 5 years of study duration

Secondary outcomes

  1. To study the clinical impact of genomic testing in terms of matched therapies prescribed by treating physicians

    * Percentage of patients who received a matched therapy against an alteration detected by ctDNA and/or tissue targeted sequencing. * Subanalysis based on physician's participation in the study.

    Time frame: Ongoing basis during 5 years of study duration

  2. Description of Overall Survival (OS) and Progression Free Survival/Time to Next Treatment (PFS/TTNT) of matched treatments.

    * Describe PFS/TTNT with treatments directed to molecular targets identified. * Describe OS from the moment of registration to the death of the patient.

    Time frame: Ongoing basis during 5 years of study duration

  3. To study the clinically actionable targets (based on ESCAT) detected using tissue targeted sequencing, and plasma ctDNA targeted sequencing.

    Proportion of patients with putatively targetable (ESCAT levels I-II) alterations detected in tissue and plasma ctDNA.

    Time frame: Ongoing basis during 5 years of study duration

  4. To study the impact of a liquid biopsy based molecular diagnostic in patients with ER+/HER2- BC whose disease progresses as a recurrence during the adjuvant treatment or as a failure of the 1L of treatment or subsequent in the metastatic setting of patie

    * ctDNA detection rate in patients with BC whose disease progresses as a recurrence during the adjuvant treatment or as a failure of the 1L of treatment or subsequent in the metastatic setting of patients from any subtype. * Frequency of mutations identified in ctDNA, distribution of VAFs and the proportion of patients with a targetable mutation in patients with BC whose disease progresses as a recurrence during the adjuvant treatment or as a failure of the 1L of treatment or subsequent in the metastatic setting of patients from any subtype.

    Time frame: Ongoing basis during 5 years of study duration

  5. To study the concordance rate for key genomic alterations between ctDNA and tumor targeted sequencing (in a subset of patients who have both samples available).

    * Concordance between ctDNA mutation status and tissue mutation status (especially in PI3K-AKT-mTOR pathway genes, ESR1 and HRD and other clinically relevant genes). * Concordance between ctDNA and tissue TMB calculations.

    Time frame: Ongoing basis during 5 years of study duration

  6. To describe the genomic landscape of MBC in a real-world population beyond clinical trials using validated targeted sequencing assays in tissue and ctDNA. Frequency of MBC gene mutations in the study population.

    Frequency of MBC gene mutations in the study population.

    Time frame: Ongoing basis during 5 years of study duration

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 24 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2025
First posted
May 28, 2025
StartActual
May 20, 2025
Primary completionEst.
May 20, 2027
CompletionEst.
May 20, 2030
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06991946
Lead sponsor
SOLTI Breast Cancer Research Group
Collaborators
Roche Farma, S.A, Menarini Group, AstraZeneca, Pfizer, Eli Lilly and Company
Responsible party
Sponsor
First posted
May 28, 2025
Start date
May 20, 2025
Primary completion
May 20, 2027 (estimated)
Completion
May 20, 2030 (estimated)
Last update
May 28, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion